Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDR | P35968 | 2/20 | 0.35 |
| ▸ | PIM1 | P11309 | 1/20 | 0.34 |
| ▸ | P2RX3 | P56373 | 1/20 | 0.33 |
| ▸ | STING1 | Q86WV6 | 1/20 | 0.33 |
| ▸ | HTR3E | A5X5Y0 | 1/20 | 0.32 |
| ▸ | HTR3B | O95264 | 1/20 | 0.32 |
| ▸ | HTR3A | P46098 | 1/20 | 0.32 |
| ▸ | HTR3D | Q70Z44 | 1/20 | 0.32 |
| ▸ | HTR3C | Q8WXA8 | 1/20 | 0.32 |
| ▸ | AAK1 | Q2M2I8 | 1/20 | 0.32 |
| ▸ | EGFR | P00533 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL1071131 | 0.99 | KDR (0.35) | KDRPIM1P2RX3STING1HTR3E | |
| Hydrochloric Acid SCHEMBL2897201 | 0.91 | STING1 (0.36) | STING1HTR3EHTR3BHTR3AHTR3D | |
| Hydrochloric Acid SCHEMBL3494749 | 0.91 | STING1 (0.36) | STING1HTR3EHTR3BHTR3AHTR3D | |
| SCHEMBL8224387 | 0.87 | KDR (0.36) | KDRPIM1P2RX3HTR3EHTR3B | |
| SCHEMBL12963793 | 0.85 | STING1 (0.30) | STING1HTR3EHTR3BHTR3AHTR3D | |
| SCHEMBL8222303 | 0.82 | PIM1 (0.41) | KDRPIM1AAK1 | |
| Hydrochloric Acid SCHEMBL1070886 | 0.81 | PIM1 (0.40) | KDRPIM1AAK1 | |
| SCHEMBL20310032 | 0.80 | STING1 (0.32) | STING1AAK1 | |
| Hydrochloric Acid SCHEMBL1073116 | 0.80 | PIM1 (0.36) | KDRPIM1P2RX3HTR3EHTR3B | |
| SCHEMBL12934499 | 0.78 | P2RX3 (0.39) | P2RX3EGFR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8377874-B2 | HCV NS3 protease inhibitors | MERCK SHARP & DOHME CORP. (US) | 2013-02-19 | — | — | US | disclosed |
| US-8377874-B2 | HCV NS3 protease inhibitors | MERCK SHARP & DOHME CORP. (US) | 2013-02-19 | — | — | US | disclosed |
| US-8309540-B2 | HCV NS3 protease inhibitors | MERCK SHARP & DOHME CORP. (US) | 2012-11-13 | — | — | US | disclosed |
| US-8309540-B2 | HCV NS3 protease inhibitors | MERCK SHARP & DOHME CORP. (US) | 2012-11-13 | — | — | US | disclosed |
| US-20110002884-A1 | THERAPEUTIC COMPOUNDS | MERCK SHARP & DOHME LLC | 2011-01-06 | — | — | US | disclosed |
| US-20110002884-A1 | THERAPEUTIC COMPOUNDS | MERCK SHARP & DOHME LLC | 2011-01-06 | — | — | US | disclosed |
| US-20100286185-A1 | HCV NS3 Protease Inhibitors | MERCK SHARP & DOHME LLC | 2010-11-11 | — | — | US | disclosed |
| US-20100286185-A1 | HCV NS3 Protease Inhibitors | MERCK SHARP & DOHME LLC | 2010-11-11 | — | — | US | disclosed |
| US-20100093779-A1 | HCV NS3 PROTEASE INHIBITORS | MERCK SHARP & DOHME LLC | 2010-04-15 | — | — | US | disclosed |
| US-20100093779-A1 | HCV NS3 PROTEASE INHIBITORS | MERCK SHARP & DOHME LLC | 2010-04-15 | — | — | US | disclosed |
| WO-2009108507-A1 | THERAPEUTIC COMPOUNDS | MERCK & CO., INC. (US) | 2009-09-03 | — | — | WO | disclosed |
| WO-2008057208-A2 | HCV NS3 PROTEASE INHIBITORS | MERCK & CO., INC. (US) | 2008-05-15 | — | — | WO | disclosed |
| WO-2008051514-A2 | HCV NS3 PROTEASE INHIBITORS | MERCK & CO., INC. (US) | 2008-05-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100093779-A1 | HCV NS3 PROTEASE INHIBITORS | HAVCR2, GTF3C3, CTSC | KDR 4626/4885PIM1 2404/4885P2RX3 3516/4885 |
| US-20110002884-A1 | THERAPEUTIC COMPOUNDS | RRP1B, ZC3HAV1, RNASE1 | KDR 3784/4885PIM1 2724/4885P2RX3 3817/4885 |
| US-20100286185-A1 | HCV NS3 Protease Inhibitors | HAVCR2, GTF3C3, CTSC | KDR 4626/4885PIM1 2404/4885P2RX3 3516/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.